Ruiwen Zhang to Antineoplastic Agents
This is a "connection" page, showing publications Ruiwen Zhang has written about Antineoplastic Agents.
Connection Strength
3.647
-
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol Rev. 2024 May 02; 76(3):414-453.
Score: 0.822
-
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. Cancer Lett. 2021 01 01; 496:16-29.
Score: 0.641
-
Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy. Cells. 2020 05 09; 9(5).
Score: 0.624
-
Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res. 2018 10 01; 78(19):5656-5667.
Score: 0.556
-
Preface. Curr Cancer Drug Targets. 2018; 18(1):2.
Score: 0.530
-
Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. Eur J Med Chem. 2021 Jan 01; 209:112866.
Score: 0.160
-
Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 2020 Jul 01; 9(7).
Score: 0.157
-
JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin avß3 signaling. Theranostics. 2020; 10(18):8036-8050.
Score: 0.157